Geninus Inc.
GENINUS Inc., a bioinformation analysis company, engages in the research and development, manufacture, and sale of genome analysis solutions in South Korea, the United States, and Asia. It offers tarhet and biomarker discovery; AI digital pathology; single cell analysis; and spatial and in-situ transcriptomics services; and SPACEINSIGHT, a cutting-edge cloud based integrated analysis platform. It… Read more
Geninus Inc. (389030) - Net Assets
Latest net assets as of September 2025: ₩13.08 Billion KRW
Based on the latest financial reports, Geninus Inc. (389030) has net assets worth ₩13.08 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩37.49 Billion) and total liabilities (₩24.41 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩13.08 Billion |
| % of Total Assets | 34.89% |
| Annual Growth Rate | 72.19% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 145.79 |
Geninus Inc. - Net Assets Trend (2018–2024)
This chart illustrates how Geninus Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Geninus Inc. (2018–2024)
The table below shows the annual net assets of Geninus Inc. from 2018 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩22.24 Billion | -35.52% |
| 2023-12-31 | ₩34.49 Billion | -20.30% |
| 2022-12-31 | ₩43.27 Billion | -16.64% |
| 2021-12-31 | ₩51.91 Billion | +562.46% |
| 2020-12-31 | ₩-11.22 Billion | -405.47% |
| 2019-12-31 | ₩-2.22 Billion | -360.44% |
| 2018-12-31 | ₩852.61 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Geninus Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5274922889000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ₩75.30 Billion | 338.60% |
| Total Equity | ₩22.24 Billion | 100.00% |
Geninus Inc. Competitors by Market Cap
The table below lists competitors of Geninus Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bigtincan Holdings Limited
PINK:BTGHF
|
$70.05 Million |
|
Granite Point Mortgage Trust Inc
NYSE:GPMT
|
$70.06 Million |
|
G2Power Co. Ltd.
KQ:388050
|
$70.07 Million |
|
Fullerton Technology Co Ltd
TW:6136
|
$70.08 Million |
|
Lotte Non-Life
KO:000400
|
$70.04 Million |
|
Intermap Technologies Corp
OTCQX:ITMSF
|
$70.03 Million |
|
Sanurhasta Mitra PT
JK:MINA
|
$70.02 Million |
|
Go Fashion (India) Limited
NSE:GOCOLORS
|
$70.02 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Geninus Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 34,485,425,830 to 22,237,105,910, a change of -12,248,319,920 (-35.5%).
- Net loss of 12,273,288,860 reduced equity.
- Share repurchases of 105,120,000 reduced equity.
- New share issuances of 105,120,000 increased equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-12.27 Billion | -55.19% |
| Share Repurchases | ₩105.12 Million | -0.47% |
| Share Issuances | ₩105.12 Million | +0.47% |
| Other Changes | ₩24.97 Million | +0.11% |
| Total Change | ₩- | -35.52% |
Book Value vs Market Value Analysis
This analysis compares Geninus Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 8.55x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 218.00x to 8.55x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | ₩26.15 | ₩5700.00 | x |
| 2019-12-31 | ₩-68.10 | ₩5700.00 | x |
| 2020-12-31 | ₩-344.20 | ₩5700.00 | x |
| 2021-12-31 | ₩1591.80 | ₩5700.00 | x |
| 2022-12-31 | ₩1326.98 | ₩5700.00 | x |
| 2023-12-31 | ₩1040.92 | ₩5700.00 | x |
| 2024-12-31 | ₩666.74 | ₩5700.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Geninus Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -55.19%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -190.12%
- • Asset Turnover: 0.20x
- • Equity Multiplier: 1.49x
- Recent ROE (-55.19%) is below the historical average (-22.66%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -36.30% | 0.00% | 0.00x | 3.92x | ₩-394.75 Million |
| 2019 | 0.00% | -224.89% | 0.11x | 0.00x | ₩-2.87 Billion |
| 2020 | 0.00% | -241.19% | 0.12x | 0.00x | ₩-8.03 Billion |
| 2021 | -17.38% | -110.88% | 0.14x | 1.12x | ₩-14.21 Billion |
| 2022 | -21.69% | -93.07% | 0.22x | 1.06x | ₩-13.71 Billion |
| 2023 | -28.08% | -139.00% | 0.17x | 1.18x | ₩-13.13 Billion |
| 2024 | -55.19% | -190.12% | 0.20x | 1.49x | ₩-14.50 Billion |
Industry Comparison
This section compares Geninus Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $209,689,906,881
- Average return on equity (ROE) among peers: -10.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Geninus Inc. (389030) | ₩13.08 Billion | -36.30% | 1.87x | $70.04 Million |
| ORIENTBIO Inc. (002630) | $67.35 Billion | -2.60% | 1.21x | $28.10 Million |
| Green Cross (005250) | $282.15 Billion | 18.83% | 0.53x | $228.88 Million |
| Green Cross Holdings Preference Shares (005257) | $1.44 Trillion | 3.01% | 0.78x | $410.72 Million |
| Pharmicell (005690) | $9.90 Billion | -119.73% | 2.00x | $438.14 Million |
| GeneOne Life Science Inc (011000) | $39.74 Billion | 0.00% | 0.49x | $53.78 Million |
| HLB Co. Ltd (028300) | $77.24 Billion | -21.40% | 1.44x | $4.11 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $25.09 Billion | 18.13% | 0.29x | $14.92 Million |
| Seoulin Bioscience Co.Ltd (038070) | $51.49 Billion | 4.00% | 0.38x | $27.72 Million |
| Hyundai Bioscience Co. Ltd (048410) | $39.30 Billion | 0.00% | 0.56x | $899.28 Million |
| iNtRON Biotechnology Inc (048530) | $64.96 Billion | -4.91% | 0.37x | $83.99 Million |